|
- 2018
Bullous Pemphigoid as an Adverse Reaction to Pembrolizumab: Two Case ReportsDOI: 10.1159/000489661 Keywords: Adverse drug reaction, Autoimmune bullous diseases, Autoimmune diseases, Bullous pemphigoid, Bullous skin disease, Malignant melanoma, Pembrolizumab, Programmed cell death 1, Checkpoint inhibitors Abstract: Checkpoint inhibitors are novel and promising treatment options for different types of cancer. Programmed cell death 1 (PD-1) inhibitors, such as pembrolizumab, have been shown to significantly raise the survival rates of disseminated malignant melanoma (MM). Autoimmune adverse reactions are very common in checkpoint inhibitors. We present 2 cases of bullous pemphigoid, as adverse reactions to pembrolizumab-treated MM
|